Peptide API

Global Peptide API Market to Reach US$33.5 Billion by 2030

The global market for Peptide API estimated at US$10.9 Billion in the year 2024, is expected to reach US$33.5 Billion by 2030, growing at a CAGR of 20.5% over the analysis period 2024-2030. GLP-1 Receptor Agonist, one of the segments analyzed in the report, is expected to record a 19.9% CAGR and reach US$17.6 Billion by the end of the analysis period. Growth in the Insulin segment is estimated at 21.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 27.4% CAGR

The Peptide API market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.9 Billion by the year 2030 trailing a CAGR of 27.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.5% and 18.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.2% CAGR.

Global Peptide API Market – Key Trends & Drivers Summarized

Why Are Peptide APIs Gaining Strategic Importance in Drug Discovery and Therapeutic Innovation?

Peptide Active Pharmaceutical Ingredients (APIs) have emerged as one of the most promising segments in modern drug development, offering high specificity, potency, and safety across a wide range of therapeutic indications. Derived from short chains of amino acids, peptide APIs are biologically active compounds that mimic endogenous molecules and interact with specific targets such as receptors, enzymes, and ion channels. Their unique mode of action, favorable pharmacokinetics, and low toxicity make them highly valuable in treating cancer, metabolic disorders, cardiovascular diseases, and rare genetic conditions.

The increasing success of peptide-based drugs such as liraglutide, semaglutide, buserelin, and leuprolide has demonstrated the clinical viability of peptides, propelling pharmaceutical firms to invest in specialized R&D and scalable manufacturing platforms. With the shift toward precision medicine and biologics, peptides are bridging the gap between small molecules and large proteins, offering opportunities for novel therapeutic modalities, including cell-penetrating peptides, peptide–drug conjugates, and multifunctional peptides. The expanding pipeline of peptide therapeutics across clinical phases underscores the rising demand for high-purity, cost-efficient peptide APIs.

How Are Advances in Synthesis Techniques and Process Optimization Enhancing API Manufacturing Capabilities?

The evolution of solid-phase peptide synthesis (SPPS), liquid-phase synthesis, and hybrid techniques has significantly improved the scalability, purity, and throughput of peptide API production. Automated peptide synthesizers, improved resins, and optimized coupling reagents now enable efficient synthesis of long, complex, and cyclic peptides with reduced reaction time and waste generation. Additionally, innovations in purification technologies such as preparative HPLC, ion-exchange chromatography, and ultrafiltration have enhanced yield and impurity control.

Manufacturers are investing in continuous manufacturing platforms and high-throughput parallel synthesis systems to reduce batch variability and enable rapid scale-up for clinical and commercial supply. Moreover, regulatory expectations for ICH Q11 compliance, process validation, and impurity profiling are driving the adoption of advanced analytics and quality-by-design (QbD) frameworks. Peptide modification strategies, including lipidation, PEGylation, and cyclization, are being integrated at the API stage to enhance bioavailability and stability. These advancements are improving cost-efficiency, regulatory compliance, and therapeutic performance across the peptide value chain.

Which Therapeutic Areas and Regional Markets Are Fueling Global Demand for Peptide APIs?

Metabolic diseases—especially Type 2 diabetes and obesity—remain the primary therapeutic drivers for peptide APIs, given the commercial success of GLP-1 analogs. Oncology, endocrinology, urology, and reproductive health are also major therapeutic domains utilizing peptides for hormone regulation, tumor suppression, and targeted therapy delivery. Peptides are increasingly being used in orphan drug development, vaccine formulations, and infectious disease management, including antimicrobial and antiviral applications.

North America and Europe dominate peptide API consumption due to strong biopharmaceutical pipelines, advanced manufacturing capabilities, and regulatory maturity. The U.S. leads in innovation, clinical trials, and commercialization, while Germany, Switzerland, and Belgium are major manufacturing hubs. Asia-Pacific—particularly India, China, South Korea, and Japan—is rapidly expanding its footprint as a cost-efficient supplier of peptide APIs and contract manufacturing services (CDMOs). Regional players are scaling up to meet the needs of both branded innovators and biosimilar developers, creating a globally integrated and competitive market landscape.

What Is Driving Long-Term Growth and Strategic Transformation in the Peptide API Market?

The growth in the peptide API market is driven by rising clinical success rates of peptide drugs, strong R&D investment in biologics, and increasing preference for targeted therapies. As pharmaceutical pipelines diversify and regulatory agencies encourage orphan drug development, peptide APIs are gaining ground as scalable, versatile therapeutic platforms. The global expansion of contract development and manufacturing services (CDMO) is also driving API outsourcing, with specialized peptide facilities in high demand for GMP-compliant, cost-competitive production.

Strategically, companies are adopting vertical integration, partnering with biotech firms for co-development, and investing in dual manufacturing sites for supply resilience. The convergence of peptide synthesis with computational biology, AI-based drug design, and nanotechnology is opening new frontiers in personalized medicine and advanced delivery systems. As regulatory frameworks continue to evolve to accommodate peptide therapeutics, API manufacturers that offer flexible, end-to-end solutions with robust quality systems are well-positioned to lead this high-growth segment.

SCOPE OF STUDY:

The report analyzes the Peptide API market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (GLP-1 Receptor Agonist, Insulin, Other Peptide Classes); Administration Route (Oral Route, Parenteral Route); Application (Type 2 Diabetes Mellitus Application, Type 1 Diabetes Application, Obesity Application, Non-alcoholic Fatty Liver Disease Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Aji Bio-Pharma Services
• AmbioPharm, Inc.
• Anthem Biosciences
• Bachem Holding AG
• Biocon Limited
• Biopeptek Pharmaceuticals
• CordenPharma International
• CPC Scientific Inc.
• Creative Peptides
• GenScript Biotech Corp.
• Hybio Pharmaceutical Co.
• Innovent Biologics
• Lonza Group AG
• Merck KGaA
• Peptide Institute, Inc.
• PeptiDream Inc.
• PeptiStar Inc.
• PolyPeptide Group
• ScinoPharm Taiwan, Ltd.
• Teva Active Pharmaceutical Ingredients

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.